➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Moodys
McKesson
McKinsey
Harvard Business School
Dow

Last Updated: October 26, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PEMFEXY

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Pemfexy

Trial ID Title Status Sponsor Phase Start Date Summary
NCT04816214 ↗ Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy Not yet recruiting Novartis Pharmaceuticals Phase 3 2021-07-15 This phase III study is designed to evaluate the anticancer activity of capmatinib in combination with osimertinib compared to platinum-pemetrexed based doublet chemotherapy as second line treatment in patients with advanced or metastatic non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation, T790M negative, mesenchymal-to-epithelial transition factor (MET) amplified who progressed following 1st/2nd generation EGFR tyrosine kinase inhibitors (TKIs) or osimertinib. The randomized part will be preceded by a safety run-in part in which the recommended dose of the combination of capmatinib and osimertinib will be confirmed.
NCT04837716 ↗ Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer Recruiting M.D. Anderson Cancer Center Phase 1 2021-03-18 This phase Ib trial finds the best dose and side effects of ensartinib and its effects when given with carboplatin, pemetrexed and bevacizumab for in treating patients with ALK-positive non-small cell lung cancer that is stage IIIC or IV, or has come back (recurrent). Ensartinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as carboplatin and pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Giving ensartinib, carboplatin, pemetrexed and bevacizumab may help to control the disease.
NCT04892953 ↗ Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy Not yet recruiting M.D. Anderson Cancer Center Phase 2 2021-07-31 This phase II trial finds out the effect of local consolidative therapy and durvalumab in treating patients with stage III non-small cell lung cancer that has 3 or fewer lesions of progression (oligoprogressive) and greater than 3 lesions of progression (polyprogressive) after chemoradiation and anti-PD-l1 therapy. Local consolidative therapy, such as surgery and/or radiation, after initial treatment may kill any remaining tumor cells. Immunotherapy with durvalumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving local consolidative therapy and durvalumab may help to control the disease.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Pemfexy

Condition Name

Condition Name for Pemfexy
Intervention Trials
Stage IIIC Lung Cancer AJCC v8 4
Stage IIIB Lung Cancer AJCC v8 3
Stage IVB Lung Cancer AJCC v8 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Pemfexy
Intervention Trials
Carcinoma, Non-Small-Cell Lung 5
Lung Neoplasms 5
Carcinoma 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Pemfexy

Trials by Country

Trials by Country for Pemfexy
Location Trials
United States 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Pemfexy
Location Trials
Texas 3
Massachusetts 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Pemfexy

Clinical Trial Phase

Clinical Trial Phase for Pemfexy
Clinical Trial Phase Trials
Phase 3 1
Phase 2/Phase 3 1
Phase 2 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Pemfexy
Clinical Trial Phase Trials
Not yet recruiting 5
Recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Pemfexy

Sponsor Name

Sponsor Name for Pemfexy
Sponsor Trials
National Cancer Institute (NCI) 3
M.D. Anderson Cancer Center 3
Novartis Pharmaceuticals 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Pemfexy
Sponsor Trials
NIH 3
Other 3
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
McKesson
Merck
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.